Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Posts filed under: Anti-Aging

Obesity, sarcopenia, aging, and health

Tweet In our  June 25, 2010 article on the Biopharmconsortium Blog, we discussed the “contrarian” views of Dr. Katherine M. Flegal and her colleagues at the National Center for Health Statistics of the Centers for Disease Control and Prevention (CDC) on the epidemiology of obesity. According to Dr. Flegal, based on epidemiological data from the…

Novartis’ breakthrough therapy for a rare muscle-wasting disease

TweetOn August 20, 2013, Novartis announced in a press release that the FDA had granted breakthrough therapy designation to its experimental agent BYM338 (bimagrumab) for treatment of the rare muscle wasting disease sporadic inclusion body myositis (sIBM). sIBM is a rare–but increasingly prevalent–disease. It is the most common cause of inflammatory myopathy in people over…

Does inflammation in the brain cause aging?

TweetThe Biopharmconsortium Blog has been following novel developments in anti-aging medicine and biology for several years. Much of the interest in this field has centered around sirtuins and potential drugs that modulate these protein deacetylase enzymes. Recently–on May 29, 2013–we published our latest blog article on sirtuins. However, we have long been aware that studies…

New findings on mechanism of activation of sirtuins may vindicate Sirtris founders

TweetThe Biopharmconsortium Blog has from time to time been following novel developments in anti-aging medicine, including attempts to develop activators of sirtuins. However, we have not had an article on sirtuins since December 1, 2010. At that time, we reported on the discontinuation by GlaxoSmithKline (GSK) of its lead sirtuin activator, SRT501, a proprietary formulation…

Identification of a novel Alzheimer’s disease pathway provides potential new avenues for drug discovery

Tweet  In August and September of 2012, we published three articles on Alzheimer’s disease on the Biopharmconsortium Blog: New genetics study supports the amyloid hypothesis of Alzheimer’s disease–but the drugs still don’t work! (August 19, 2012.) Here we go again–Lilly’s Alzheimer’s drug solanezumab fails to show efficacy in Phase 3, but company is “encouraged” by…

The great metformin mystery–genomics, diabetes, and cancer

Tweet  Metformin (Bristol-Myers Squibb’s Glucophage, generics), an oral biguanide antidiabetic drug, is the most widely prescribed agent for treatment of type 2 diabetes. The drug mainly works by lowering glucose production by the liver, and thus lowering fasting blood glucose. Although metformin–approved in the United States in 1994, and in Europe prior to that–has been…

GlaxoSmithKline stops development of resveratrol drug SRT501

TweetIn statements to Fierce Biotech and to the Myeloma Beacon, GlaxoSmihtKline (GSK) said that it has stopped all development of its proprietary resveratrol formulation SRT501. Thanks also to the “In the Pipeline” blog for the information on the Myeloma Beacon statement. As you all may recall, GSK acquired the sirtuin-pathway specialty company Sirtris (Cambridge, MA)…

More on anti-aging research: Continuing controversy, opportunity, and good news

Tweet 1. Continuing Controversy In our blog post on 10 February 2010, we discussed the controversy over Sirtris/GlaxoSmithKline’s reseveratrol formulation, and its second-generation sirtuin-1 (SIRT1) activators. Researchers at Amgen and Pfizer found that the apparent in vitro activation of SIRT1 by these compounds was an artifact of the experimental method used by Sirtris researchers. The…

Update on anti-aging biology, sirtuins, and Sirtris/GlaxoSmithKline

TweetOn November 8, 2009, we posted an article entitled “Anti-aging biology: new basic research, drug development, and organizational strategy” on this blog. This article focused on new findings in anti-aging biology, their applications to drug discovery and development, and on how this field has affected the organizational strategy of GlaxoSmithKline (GSK). GSK acquired Sirtris for…

Anti-aging biology: new basic research, drug development, and organizational strategy

TweetIn the 2 October issue of Science (the “Ardipithecus ramidus issue”), there was a Perspective (authored by Matt Kaeberlein and Pankaj Kapahi) and a Report (authored by Colin Selman and his colleagues) on recent findings in anti-aging biology. Since the late 1980s, researchers have found that caloric restriction (CR) (reduction in caloric intake while maintaining…